TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Soleno Therapeutics ( (SLNO) ) has issued an update.
On November 11, 2025, Soleno Therapeutics announced that its Board of Directors approved an accelerated share repurchase agreement with Jefferies LLC to buy back $100 million of its common stock. This move reflects the company’s confidence in its commercial launch and the potential of VYKAT XR as a foundational therapy for Prader-Willi syndrome. Soleno achieved profitability in the third quarter of 2025 and views the repurchase as an attractive opportunity, with the transaction expected to conclude in the first quarter of 2026.
The most recent analyst rating on (SLNO) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.
Spark’s Take on SLNO Stock
According to Spark, TipRanks’ AI Analyst, SLNO is a Underperform.
Soleno Therapeutics shows high risk due to its lack of revenue and reliance on external financing. However, it maintains a solid equity base and is experiencing positive technical momentum, suggesting speculative interest. The valuation is typical for an early-stage biotech, with potential upside reliant on successful R&D outcomes.
To see Spark’s full report on SLNO stock, click here.
More about Soleno Therapeutics
Soleno Therapeutics is a biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR, is an extended-release tablet for managing hyperphagia in individuals with Prader-Willi syndrome.
Average Trading Volume: 2,133,556
Technical Sentiment Signal: Sell
Current Market Cap: $2.49B
See more insights into SLNO stock on TipRanks’ Stock Analysis page.